Zura Bio (FRA:94E) Piotroski F-Score: 4 (As of Jul. 27, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:94E Zura Bio Ltd FRA:94E
25 GF Score
Price €4.58
View Full Analysis

What is Zura Bio Piotroski F-Score?

Zura Bio FRA:94E -1.29% 25 Piotroski F-Score is 4 as of Jul. 27, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:94E with a GF Score™ of 25/100. Among 1,331 Biotechnology companies, Zura Bio ranks better than 73.93% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zura Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zura Bio's Piotroski F-Score or its related term are showing as below:

FRA:94E' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 4
Current: 4

During the past 4 years, the highest Piotroski F-Score of Zura Bio was 4. The lowest was 2. And the median was 4.

Zura Bio  (FRA:94E) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zura Bio Piotroski F-Score Related Terms


Zura Bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zura Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zura Bio Piotroski F-Score Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A 3.00 4.00 3.00

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 2.00 3.00 3.00 4.00

FRA:94E vs ASMB, ARTV, EIKN: Piotroski F-Score Comparison

For the Biotechnology subindustry, Zura Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zura Bio's Piotroski F-Score falls into.


FRA:94E
25GF Score
Zura Bio Ltd FRA:94E
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -13.866 + -15.37 + -14.667 + -20.953 = €-64.86 Mil.
Cash Flow from Operations was -13.898 + -13.158 + -19.025 + -16.368 = €-62.45 Mil.
Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(159.559 + 136.817 + 122.633 + 97.312 + 197.774) / 5 = €142.819 Mil.
Total Assets at the begining of this year (Mar25) was €159.56 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €196.36 Mil.
Total Current Liabilities was €10.16 Mil.
Net Income was -9.596 + -18.653 + -13.012 + -16.134 = €-57.40 Mil.

Revenue was 0 + 0 + 0 + 0 = €0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = €0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(83.244 + 176.046 + 170.353 + 171.454 + 159.559) / 5 = €152.1312 Mil.
Total Assets at the begining of last year (Mar24) was €83.24 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €158.82 Mil.
Total Current Liabilities was €19.51 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zura Bio's current Net Income (TTM) was -64.86. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zura Bio's current Cash Flow from Operations (TTM) was -62.45. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-64.856/159.559
=-0.40647033

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-57.395/83.244
=-0.68947912

Zura Bio's return on assets of this year was -0.40647033. Zura Bio's return on assets of last year was -0.68947912. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zura Bio's current Net Income (TTM) was -64.86. Zura Bio's current Cash Flow from Operations (TTM) was -62.45. ==> -62.45 > -64.86 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/142.819
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/152.1312
=0

Zura Bio's gearing of this year was 0. Zura Bio's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=196.358/10.159
=19.32847721

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=158.815/19.51
=8.14018452

Zura Bio's current ratio of this year was 19.32847721. Zura Bio's current ratio of last year was 8.14018452. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zura Bio's number of shares in issue this year was 112.223. Zura Bio's number of shares in issue last year was 92.964. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Zura Bio's gross margin of this year was . Zura Bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0/159.559
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/83.244
=0

Zura Bio's asset turnover of this year was 0. Zura Bio's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zura Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Zura Bio (FRA:94E) has a Piotroski F-Score of 4 as of Jul. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zura Bio and its competitors. This is near median its historical median of 4.00. Over the past decade, Zura Bio's Piotroski F-Score has ranged from 2.00 to 4.00. According to the industry distribution chart, Zura Bio ranks #347 out of 1331 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Zura Bio's Piotroski F-Score too high?
Zura Bio's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. The Biotechnology industry median Piotroski F-Score is 3.00. Zura Bio's value of 4 is 33.3% above this industry median. Based on the distribution chart, Zura Bio ranks #347 out of 1331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Piotroski F-Score compare to ASMB and ARTV?
According to the Biotechnology industry distribution chart, Zura Bio ranks #347 out of 1331 companies for Piotroski F-Score. This puts Zura Bio in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Zura Bio's value of 4 is 33.3% above this benchmark. Historically, Zura Bio's own Piotroski F-Score has ranged from 2.00 to 4.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Zura Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zura Bio's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zura Bio and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zura Bio's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (FRA:94E) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zura Bio (FRA:94E), the current Piotroski F-Score is 4 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zura Bio Business Description

Other Exchanges ZURA:USA
Address 1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score

Get the complete analysis for FRA:94E

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.58
Price